Summary
To try to explain the wide therapeutic range of cyclosporin A, we examined its effects on physiological functions of skin and responses to immunological and inflammatory stimuli during and before or after administration of 5 mg/kg/day of cyclosporin A in the treatment of various skin diseases.
Pilocarpine-stimulated, sweat rate (10 patients), sebum excretion rate (10), scalp hair growth rate (8) and epidermal proliferation in response to tape-stripping (7) were not affected by cyclosporin A; nail growth rate was unaltered in patients without psoriasis (12), but was significantly slowed by treatment in patients with psoriasis (7) who had abnormally rapid growth before treatment.
Induction of cell-mediated sensitisation to 2,4-dinitrochlorobenzene (DNCB) was inhibited by cyclosporin A treatment (22 patients), but 7 patients sensitised to DNCB before cyclosporin treatment reacted normally to DNCB challenge during treatment. The immediate hypersensitivity response to intradermal house dust mite antigen was increased during treatment in 8 patients with atopy.
Weal responses to histamine (9 patients) and compound 48/80 (12), the 24 hour erythemal response to ultraviolet B (UVB) irradiation (10) and the inflammatory response to topical leukotriene B4 (16) were not affected, but cyclosporin A produced a striking inhibition of anthralin inflammation (21).
Since the methods we used will have detected all but minor changes, we conclude that cyclosporin A has no gross physiological effects on the skin and is not cytostatic; hypertrichosis must be due to a prolonged hair cycle. Secondly, cyclosporin A (a) impairs induction of cell-mediated sensitisation in doses which permit some continued expression, but (b) increases immediate hypersensitivity. Thirdly, cyclosporin A has no general anti-inflammatory effect, but we have found a novel and specific inhibitory effect on anthralin inflammation, the mechanism of which may underlie some of its therapeutic effects. The therapeutic effect of cyclosporin A may not be due solely to its immune effects, and other activities such as the anti-inflammatory effect we found need further exploration.
Similar content being viewed by others
References
Amlott PL, Hayes AE, Gray D, Gordon-Smith E, Humphrey JH. Human immune responses in vivo to protein (KLH) and polysaccharide (DNP-Ficoll) neoantigens: normal subjects compared with bone marrow transplant patients on cyclosporin. Clinical and Experimental Immunology 64: 125–135, 1986
Barthelemy H, Thivolet J, Cambazard F, Benbdelac A, Mauduit G, et al. La ciclosporine dans le traitement de la pemphigoide bulleuse. Annals of Dermatology and Venereology 113: 309–313, 1986
Bencini PL, Montagnino G, Crosti C, Sala F, De Vecchi A. Acne in a kidney transplant patient treated with cyclosporin A. British Journal of Dermatology 115: 396–397, 1986
Bendtzen K, Trede N, Andersen V, Benxiden G. Cyclosporin for polymyositis. Lancet 2: 792–793, 1984
Bennett WM, Pulliam JP. Cyclosporin nephrotoxicity. Annals of Internal Medicine 305: 267–273, 1983
Bennett WM, Elzinga L, Kelley V. Pathophysiology of cyclosporin nephrotoxicity: role of eicosanoids. Transplantation Proceedings 20(Suppl. 3): 628–633, 1988.
Calne RY, Rolles K, White DG, Thiru S, Evans DB, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric transplants: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2: 1033–1036, 1979
Camp RA, Russell Jones R, Brain S, Woollard P, Greaves M. Production of intraepidermal abscesses by topical application of leukotriene B4. Journal of Investigative Dermatology 82: 202–204, 1984.
Chen SS. Cyclosporin A acts as a potent co-stimulator in up-regulation of IgE antibody synthesis and expression of receptor of IgE. Transplantation Proceedings 20(Suppl. 2): 92–102, 1988
Cook J, Shuster S. Histamine weal formation and absorption in man. British Journal of Pharmacology 69: 579–585, 1980
Crounse RG, van Scott ES. Changes in scalp hair roots as a measure of toxicity for cancer chemotherapeutic agents. Journal of Investigative Dermatology 35: 83–90, 1960
Curley RK, Macfarlane AW, Vickers CF. Pyoderma gangrenosum treated with cyclosporin A. British Journal of Dermatology 113: 601–604, 1985
Dawber R. Fingernail growth in normal and psoriatic patients. British Journal of Dermatology 82: 454–471, 1970
Dawber R. The nails. In Rook, et al. (Eds) Textbook of dermatology, 4th ed., Vol. 3, pp. 2039–2073, Blackwell Scientific Publication, Oxford, 1986
Diffey BL, Oliver RJ, Farr PM. A portable instrument for quantifying erythema induced by ultraviolet radiation. British Journal of Dermatology 111: 663–672, 1984
Esa AH, Paxman DG, Noga SJ, Hess AD. Sensitivity of monocyte subpopulations to cyclosporin A: arachidonate metabolism and in vitro antigen presentation. Transplantation Proceedings 20(Suppl. 2): 80–86, 1988
Farr PM, Diffey BL. The erythemal response of human skin to ultraviolet radiation. British Journal of Dermatology 113: 65–75, 1985
Farr PM, Diffey BL. A quantitative study of the effect of topical indomethacin on cutaneous erythema induced by UVB and UVC radiation. British Journal of Dermatology 115: 453–466, 1986
Farr PM, Diffey BL, Humphreys F. A quantitative study of the effect of terfenadine on cutaneous erythema induced by UVB and UVC irradiation. Journal of Investigative Dermatology 87: 771–774, 1986
Finnen MJ, Lawrence CM, Shuster S. Inhibition of dithranol inflammation by free radical scavengers. Lancet 2: 1129–1130, 1984
Harper JI, Keat JCS, Staughton RCD. Cyclosporin A for psoriasis. Lancet 2: 981–982, 1984
Hess AD, Esa AH, Colombani PM. Mechanisms of action of cyclosporine: effect on cells of the immune system and subcellular events in T cell activation. Transplantation Proceedings 20(Suppl. 2): 29–40, 1988
Humphreys F, Shuster S. The effect of nedocromil on weal reactions in human skin. British Journal of Clinical Pharmacology 24: 405–408, 1987
Humphreys F, Krause LB, Shuster S. The effects of astemizole and indomethacin on weal and flare reactions to histamine, 48/80, and house dust mite antigen. British Journal of Dermatology 116: 435, 1987
Jones HF, Lewis CF, McMarlin SL. Allergic contact sensitivity in atopic dermatitis. Archives of Dermatology 107: 217–222, 1973
Katakkar SB. Cyclosporin and pure red cell aplasia. Transplantation Proceedings 20(Suppl. 4): 314–316, 1988
Kelsey PR, Schofield KP, Geary CG. Refractory idiopathic thrombocytopenic purpura (ITP) treated with cyclosporin. British Journal of Haematology 60: 197–198, 1985
Kragballe K, Ternowitz T. Treatment with cyclosporin A in psoriasis results in inhibition of the inflammatory response to intradermal injections of leukotriene B4 and CsA. Skin Pharmacology 1: 68–69, 1988.
Lawrence CM, Shuster S. Comparison of ultrasound and caliper measurements of normal and inflamed skin thickness. British Journal of Dermatology 112: 195–200, 1985a
Lawrence CM, Shuster S. Mechanism of anthralin inflammation, I; dissociation of response to clobetasol and indomethacin. British Journal of Dermatology 113: 107–115, 1985b
Lawrence CM, Shuster S. Effect of arachidonic acid on anthralin inflammation. British Journal of Clinical Pharmacology 24: 125–131, 1987
Lookingbill DP, Cunliffe WJ. A direct gravimetric method for measuring sebum excretion rate. British Journal of Dermatology 114: 75–81, 1986
Marks J. Psoriasis. British Medical Journal 293: 509, 1986
Miller RA, Shen JY, Rea TH, Harnisch JP. Treatment of chronic erythema nodosum leprosum with cyclosporin A produces clinical and immunohistologic remission. International Journal of Leprosy and Other Mycobacterial Diseases 55: 441–449, 1987
Mitchell EB, Crow J, Chapman MD, Jouhal SS, Pope FM, Platts-Mills TAE. Basophils in allergen-induced patch test sites in atopic dermatitis. Lancet 1: 127–130, 1982
Mueller W, Hermann B. Cyclosporin A for psoriasis. New England Journal of Medicine 301: 555, 1979
Norris PG, Schofield O, Camp RDR. A study of the role of house dust mite in atopic dermatitis. British Journal of Dermatology 118: 435–440, 1988
Nussenblatt RB, Palestine AG, Rook AH, Sher I, Wacken WB, et al. Treatment of ocular inflammatory diseases with cyclosporin A. Lancet 2: 235–238, 1983
Palestine AG, Nussenblatt RB, Chan CC. Side-effects of cyclosporin in patients not undergoing transplantation. American Journal of Medicine 77: 652–656, 1984
Ponticelli C, Rivolta E. Cyclosporine in nephrotic syndrome. Transplantation Proceedings 20(Suppl. 4): 253–258, 1988
Ralfs I, Dawber R, Ryan T, Duffill M, Wright NA. The kinetics of metaphase arrest in human psoriatic epidermis: an examination of optimal experimental conditions for determining the birth rate. British Journal of Dermatology 104: 231–242, 1981
Rees J, Shuster S. Pubertal induction of sweat gland activity. Clinical Science 60: 689–692, 1981
Rogge JL, Hanifin JF. Immunodeficiencies in severe atopic eczema. Archives of Dermatology 112: 1391–1396, 1976
Selleri C, Catalano L, Alfinito F, De Rosa G, Vaglio S, et al. Cyclosporin A in adult onset cyclic neutropenia. British Journal of Haematology 68: 137–138, 1988
Seymour RA, Smith DG, Roghers SR. The comparative effects of azathioprine and cyclosporin A on some gingival health parameters of renal transplant recipients. Journal of Clinical Periodontology 14: 610–613, 1987
Shuster S. Cyclosporin in dermatology. Transplantation Proceedings 20(Suppl. 4): 19–22, 1988.
Van Rijthoven AWAM, Dijkman BAC, Goei Thè HS, Henery J, Montnor Becker ZLMB, et al. Cyclosporin A treatment for rheumatoid arthritis: a placebo-controlled, double blind, multicentre study. Annals of Rheumatic Diseases 45: 726–730, 1986
Van Joost T, Stolz E, Heule F. Efficacy of low-dose cyclosporine in severe atopic skin disease. Archives of Dermatology 123: 166–167, 1987
Van der Heyden AAPAM, van Oers MHJ, Cornelissen P, Yons SL, Wimink JM, et al. The influence of cyclosporin A treatment on immune response in vitro and in vivo in kidney transplant recipients. Transplantation Proceedings 20(Suppl. 2): 190–195, 1988
White SI, Friedmann PS, Moss C, Simpson JM. The effect of altering area of application and dose per unit area on sensitization by DNCB. British Journal of Dermatology 115: 663–668, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Munro, C.S., Higgins, E.M., Ramsay, B. et al. The Mode of Action of Cyclosporin. Drug Invest 2, 1–9 (1990). https://doi.org/10.1007/BF03259395
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259395